Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Not Recruiting

Trial ID: NCT00004228

Age - 1 Year-30 Years Condition - Lymphomas: Non-Hodgkin, Pediatric Cancer Gender - All Accepting Healthy Volunteers - No

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.

Official Title

Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma

Stanford Investigator(s)

Neyssa Marina

Eligibility


DISEASE CHARACTERISTICS:

   - Newly diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic
   lymphoma*

      - Less than 25% tumor cells in the bone marrow

      - Previously untreated (prior intrathecal cytarabine allowed if protocol therapy
      begins within 72 hours)

      - Stage III or IV disease

   - NOTE: *Localized lymphoblastic lymphoma is closed to accrual as of 10/2005

PATIENT CHARACTERISTICS:

Age:

   - 1 to 30

Performance status:

   - Not specified

Life expectancy:

   - Not specified

Hematopoietic:

   - Not specified

Hepatic:

   - Not specified

Renal:

   - Not specified

Cardiovascular:

   - Adequate cardiac function

PRIOR CONCURRENT THERAPY:

Biologic therapy:

   - Not specified

Chemotherapy:

   - See Disease Characteristics

Endocrine therapy:

   - Emergency steroid therapy (if required) must be started within 72 hours prior to
   protocol therapy

Radiotherapy:

   - Emergency radiotherapy (if required) must be started within 72 hours prior to protocol
   therapy

Surgery:

   - Not specified

Other:

   - No other prior therapy except for emergency treatment of airway obstruction and/or
   superior vena cava syndrome

View More
View Less

Intervention(s):

drug: vincristine sulfate

radiation: radiation therapy

drug: cyclophosphamide

drug: cytarabine

drug: daunorubicin hydrochloride

drug: dexamethasone

drug: doxorubicin hydrochloride

drug: leucovorin calcium

drug: mercaptopurine

drug: methotrexate

drug: prednisone

drug: thioguanine

drug: asparaginase

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine